Has Samantha Braun, APRN received payments from drug or device companies?

Yes. Drug and device makers reported $3,862 in general payments to Samantha Braun, APRN across 114 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Samantha Braun, APRN did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Samantha Braun, APRN come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Samantha Braun, APRN

Family · Blue Ash, OHNPI 1013636380

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,247 of the $3,862 with a category attached, or 84.1%. It is spread thinly across 26 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,862in general payments, 2019–2025

Across 114 payments — averaging $33.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$599
AstraZeneca$562
Astellas Pharma US Inc$463
AbbVie$456
Pfizer$228
Novartis$201
plus $1K from 20 others

What the payments were for

Food & beverage$3,24784%
Education$61416%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	15	$599
AstraZeneca	8	$562
Astellas Pharma US Inc	6	$463
AbbVie	15	$456
Pfizer	13	$228
Novartis	11	$201
Merck	7	$163
Johnson & Johnson	6	$145
Takeda Pharmaceuticals U.S.A., Inc.	3	$137
Amgen	1	$131
Regeneron Healthcare Solutions, Inc.	2	$128
Gilead	6	$124
Pharmacosmos Therapeutics Inc.	1	$108
Lilly USA, LLC	4	$70
AVEO Pharmaceuticals, Inc.	2	$59
Daiichi Sankyo Inc.	2	$47
Sanofi-aventis U.S. LLC	1	$42
Jazz Pharmaceuticals Inc.	2	$40
Eisai Inc.	2	$38
Bristol Myers Squibb	1	$26
Sobi, Inc	1	$18
Rigel Pharmaceuticals, Inc.	1	$17
Incyte Corporation	1	$17
Adaptive Biotechnologies Corporation	1	$16
Amneal Pharmaceuticals LLC	1	$15
Legend Biotech USA Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,862 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio →

Medicare billing

Part B allowed, 2024

$29,455

Medicare patients

165

Services billed

1,974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ondansetron Hcl	70	$2,053
Prochlorperazine Maleate	53	$1,209
Oxycodone Hcl	14	$371
Pregabalin	11	$255
Potassium Chloride	11	$153
Prednisone	15	$116
Omeprazole	14	$75
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine	12	$73
Ciprofloxacin Hcl	11	$28

Paid to pharmacies, not to this prescriber.

Other family in Blue Ash

Leigh Ann PanschDayton$670K
Natalie BelliniMayfield Heights$582K
Kaitlyn LovettMontgomery$286K
Amy RossDayton$281K
Renee OttSandusky$179K
Megan MillerSpringfield$156K
George KnightCincinnati$130K
Jillian HuntCincinnati$116K
Florence StewartNew Albany$113K
Kirt MunsonToledo$108K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →